Diquafosol: Difference between revisions
CSV import |
CSV import |
||
| Line 1: | Line 1: | ||
'''Diquafosol''' is a | == Diquafosol == | ||
[[File:Diquafosol.svg|thumb|right|Chemical structure of Diquafosol]] | |||
'''Diquafosol''' is a pharmaceutical drug used primarily in the treatment of [[dry eye syndrome]]. It is a purinergic P2Y2 receptor agonist that stimulates the secretion of water and mucin from the [[conjunctival epithelium]], thereby enhancing the tear film and improving ocular surface health. | |||
== Mechanism of Action == | == Mechanism of Action == | ||
Diquafosol works by activating the P2Y2 receptors located on the surface of the [[conjunctival epithelial cells]]. This activation leads to an increase in intracellular calcium levels, which in turn stimulates the secretion of water, mucin, and other components of the tear film. The enhanced tear film helps to lubricate the eye, providing relief from the symptoms of dry eye. | |||
== | == Clinical Use == | ||
Diquafosol is typically administered as an ophthalmic solution. It is used in patients who suffer from dry eye disease, a condition characterized by insufficient tear production or excessive tear evaporation. By improving the quality and quantity of the tear film, diquafosol helps to alleviate symptoms such as irritation, redness, and blurred vision. | |||
== Side Effects == | == Side Effects == | ||
Common side effects of | Common side effects of diquafosol may include mild eye irritation, burning sensation, and temporary blurred vision. These side effects are generally mild and transient. Patients are advised to contact their healthcare provider if they experience severe or persistent symptoms. | ||
== | == Related Pages == | ||
* [[Dry eye syndrome]] | * [[Dry eye syndrome]] | ||
* [[ | * [[Conjunctival epithelium]] | ||
* [[ | * [[Purinergic receptor]] | ||
[[Category:Ophthalmology]] | [[Category:Ophthalmology]] | ||
[[Category: | [[Category:Pharmaceutical drugs]] | ||
Latest revision as of 03:49, 13 February 2025
Diquafosol[edit]
Diquafosol is a pharmaceutical drug used primarily in the treatment of dry eye syndrome. It is a purinergic P2Y2 receptor agonist that stimulates the secretion of water and mucin from the conjunctival epithelium, thereby enhancing the tear film and improving ocular surface health.
Mechanism of Action[edit]
Diquafosol works by activating the P2Y2 receptors located on the surface of the conjunctival epithelial cells. This activation leads to an increase in intracellular calcium levels, which in turn stimulates the secretion of water, mucin, and other components of the tear film. The enhanced tear film helps to lubricate the eye, providing relief from the symptoms of dry eye.
Clinical Use[edit]
Diquafosol is typically administered as an ophthalmic solution. It is used in patients who suffer from dry eye disease, a condition characterized by insufficient tear production or excessive tear evaporation. By improving the quality and quantity of the tear film, diquafosol helps to alleviate symptoms such as irritation, redness, and blurred vision.
Side Effects[edit]
Common side effects of diquafosol may include mild eye irritation, burning sensation, and temporary blurred vision. These side effects are generally mild and transient. Patients are advised to contact their healthcare provider if they experience severe or persistent symptoms.
